Related content

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors

By  

Oncology Reports, Vol. 33, Iss. 3, 2015-01 ,pp. : 1499-1504

Spandidos Publications

Access to resources Recommend Favorite

Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung

By Lee Youngjoo   Han Ji-Youn   Kim Heung   Yun Tak   Lee Geon   Kim Hyae   Lee Jin  

Journal of Neuro-Oncology, Vol. 115, Iss. 1, 2013-10 ,pp. : 95-101

Springer Publishing Company

Access to resources Recommend Favorite

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

By Raizer Jeffrey  

Journal of Neuro-Oncology, Vol. 74, Iss. 1, 2005-08 ,pp. : 77-86

Springer Publishing Company

Access to resources Recommend Favorite

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

By Rosell Rafael   Taron Miquel   Sanchez Jose Javier   Paz-Ares Luis  

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 277-283

Future Medicine

Access to resources Recommend Favorite